This is a promotional website intended for UK Healthcare Professionals (HCPs) only. Please note that some content is only relevant for HCPs practising in Great Britain.

Cholera vaccine


Cholera vaccine (inactivated, oral) 
DUKORAL® is an inactivated cholera vaccine. Help protect your travellers against cholera.


Key facts

  • Licensed for adults and children from 2 years of age to help protect against cholera2
  • Contains inactivated Vibrio cholera O1 bacteria and the recombinant non-toxic B-subunit of the cholera toxin (rCTB)2
  • Has demonstrated 78% – 86% protection against cholera, across 3 continents3-5
  • A drinkable formulation which is convenient and easy to take2
  • No special requirements concerning the water; Dukoral can be made with either cool or chlorinated water2
  • A booster should be given within 2 years for adults and children over 6 years of age and within 6 months for children aged 2 – 6 years of age2
  • Immunisation protects specifically against V. cholerae serogroup O1 and is not a substitute for adhering to protective hygiene measures1
  • Established vaccine that is generally well-tolerated1
  • The most frequently reported adverse reactions (uncommon: ≥ 1/1,000 to <1/100) in clinical trails include gastrointestinal symptoms, including abdominal pain, cramps, gurgling, discomfort, diarrhoea and headaches.2
  • DUKORAL® is contraindicated in individuals who have had an anaphylactic reaction to any vaccine component or formaldehyde1

How you should administer DUKORAL®1



View Prescribing InformationFurther information on SMPC Further information on PIL

Place an order


  1. Public Health England. Immunisation against infectious disease. Cholera: the green book, chapter 14. December 2013. Available online: (Last accessed March 2023).
  2. Valneva UK Limited. DUKORAL® Summary of Product Characteristics. February 2023. Available online: (Last accessed March 2023).
  3. Clemens JD, Sack DA, Harris JR et al. Field trial of oral cholera vaccines in Bangladesh. Lancet 1988;158(1):60-68.
  4. Sanchez JL, Vasquez B, Begue RE et al. Protective efficacy of oral whole-cell/recombinant-B- subunit cholera vaccine in Peruvian military recruits. Lancet 1994;344:1273–1276.
  5. Lucas M, Deen JL, von Seidlein L et al. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N Engl J Med 2005; 352: 757–767.

Adverse events should be reported.
Reporting forms and information can be found at or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to the Valneva UK Ltd Medical Information department on Tel: 01506 446608 or via email:

2024 - Please use a modern browser